Your browser doesn't support javascript.
loading
Differences in overall survival of penile cancer patients versus population-based controls.
Scheipner, Lukas; Tappero, Stefano; Piccinelli, Mattia Luca; Barletta, Francesco; Garcia, Cristina Cano; Incesu, Reha-Baris; Morra, Simone; Tian, Zhe; Saad, Fred; Shariat, Shahrokh F; Terrone, Carlo; De Cobelli, Ottavio; Briganti, Alberto; Chun, Felix K H; Tilki, Derya; Longo, Nicola; Seles, Maximilian; Ahyai, Sascha; Karakiewicz, Pierre I.
Affiliation
  • Scheipner L; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Tappero S; Department of Urology, Medical University of Graz, Graz, Austria.
  • Piccinelli ML; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Barletta F; Department of Urology, IRCCS Policlinico San Martino, Genova, Italy.
  • Garcia CC; Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, Italy.
  • Incesu RB; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Morra S; Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy.
  • Tian Z; Università degli Studi di Milano, Milan, Italy.
  • Saad F; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Shariat SF; Soldera Prostate Cancer Lab, Unit of Urology/Division of Oncology, Gianfranco, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Terrone C; Vita-Salute San Raffaele University, Milan, Italy.
  • De Cobelli O; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Briganti A; Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt am Main, Germany.
  • Chun FKH; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Tilki D; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
  • Longo N; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Seles M; Department of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy.
  • Ahyai S; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
  • Karakiewicz PI; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Int J Urol ; 31(3): 274-279, 2024 Mar.
Article de En | MEDLINE | ID: mdl-38014575
ABSTRACT

PURPOSE:

To assess whether 5-year overall survival (OS) of squamous cell carcinoma of the penis (SCCP) patients differs from age-matched male population-based controls.

METHODS:

We relied on the Surveillance Epidemiology and End Results database (2004-2018) to identify newly diagnosed (2004-2013) SCCP patients. For each case, we simulated an age-matched control (Monte Carlo simulation), relying on the Social Security Administration (SSA) Life Tables with 5 years of follow-up. We compared OS between SCCP patients and population-based controls in a stage-specific fashion. Smoothed cumulative incidence plots displayed cancer-specific mortality (CSM) versus other-cause mortality (OCM).

RESULTS:

Of 2282 SCCP patients, the stage distribution was as follows stage I 976 (43%) versus stage II 826 (36%) versus stage III 302 (13%) versus stage IV 178 (8%). At 5 years, OS of SCCP patients versus age-matched population-based controls was as follows stage I 63% versus 80% (Δ = 17%), stage II 50% versus 80% (Δ = 30%), stage III 39% versus 84% (Δ = 45%), stage IV 26% versus 87% (Δ = 61%). At 5 years, CSM versus OCM in SCCP patients according to stage was as follows stage I 12% versus 24%, stage II 22% versus 28%, stage III 47% versus 14%, and stage IV 60% versus 14%.

CONCLUSION:

SCCP patients exhibit worse OS across all stages. The difference in OS at 5 years between SCCP and age-matched male population-based controls ranged from 17% to 61%. At 5 years, CSM accounted for 12% to 60% of all deaths, across all stages.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs du pénis Limites: Humans / Male Langue: En Journal: Int J Urol Sujet du journal: UROLOGIA Année: 2024 Type de document: Article Pays d'affiliation: Canada

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs du pénis Limites: Humans / Male Langue: En Journal: Int J Urol Sujet du journal: UROLOGIA Année: 2024 Type de document: Article Pays d'affiliation: Canada
...